A randomised, double-blind, placebo-controlled trial to assess the effects of EP395 following an inhaled endotoxin challenge in healthy adults

2024-516187-29-00 Protocol EP395-006 Human pharmacology (Phase I) - Other Ended

Start 20 Feb 2025 · End 18 Nov 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol EP395-006

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 65
Countries 1
Sites 1

Healthy volunteers [targeted indication: chronic obstructive pulmonary disease (COPD)]

Key facts

Sponsor
EpiEndo Pharmaceuticals ehf.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
20 Feb 2025 → 18 Nov 2025
Decision date (initial)
2024-11-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516187-29-00
WHO UTN
U1111-1310-4490
ClinicalTrials.gov
NCT06677918

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteers [targeted indication: chronic obstructive pulmonary disease (COPD)]

VersionLevelCodeTermSystem organ class
26.1 PT 10009033 Chronic obstructive pulmonary disease 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

EpiEndo Pharmaceuticals ehf.

Sponsor organisation
EpiEndo Pharmaceuticals ehf.
Address
Bjargargata 1
City
Reykjavik
Postcode
102
Country
Iceland

Scientific contact point

Organisation
EpiEndo Pharmaceuticals ehf.
Contact name
Sponsor Clinical Trial Information

Public contact point

Organisation
EpiEndo Pharmaceuticals ehf.
Contact name
Sponsor Clinical Trial Information

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 65 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM
Division Director Airway Research, Feodor-Lynen-Str. 15, Division of Clinical Airway Research, Hannover

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-02-20 2025-11-18 2025-02-20 2025-10-15

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-20 Germany Acceptable
2024-11-14
2024-11-15
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-26 Germany Acceptable
2024-11-14
2025-02-26